Molecular mechanisms
Discovering hidden molecular cargo and selective therapeutic effects of stem cells and secreted EV subpopulations.
Precision therapy · extracellular vesicles · AI
Extracellular Vesicle-Based Precise Therapy for Cancer
EviCure is developing a platform that combines therapeutic extracellular vesicles with targeted delivery and AI-assisted development for solid-tumor applications.
AI-guided discovery, validation and scale-up
AI-based development
Precision introduced across the development process
From identifying molecular cargo to validating therapeutic EV subpopulations and monitoring scale-up, EviCure combines experimental disease models with AI-driven analysis.
Therapeutic EVs
Evaluating combined anti-tumor activity and targeted-delivery potential in human tumor models.
Validation
Bridging animal-model results to humans to improve prediction validity and clinical applicability.
AI-based scale-up
Real-time EV monitoring and AI analysis to support precise, reproducible production.
Competitive advantages
A technology platform built around therapeutic EVs
EV libraries combined with AI support precise production, therapeutics and drug delivery.
Technology platform
EV libraries and AI applied across discovery, production and targeted therapeutic delivery.
First product to market
PL-Ex1 is the lead EV-based program for refractory NSCLC and other solid-tumor applications.
Long-term roadmap
A platform designed to extend toward additional solid-cancer indications.
Extensive IP
Granted and pending patent activity arising from the company’s research program.
Experienced team
Experience spanning translational science, molecular biology, entrepreneurship and data science.
Growing market
Focused on cancer therapy, a global market driven by the prevalence of solid tumors.
Want to know more?
Connect with EviCure about the platform, PL-Ex1 and development opportunities.